Neovacs S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was EUR 0.538289 million compared to EUR 0.012555 million a year ago. Net loss was EUR 8.74 million compared to EUR 3.55 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1499 EUR | -12.13% | -12.44% | -92.50% |
May. 29 | Neovacs: mRNA approach validated in preclinical trial | CF |
May. 27 | Neovacs: collaboration contract with INSERM team | CF |
1st Jan change | Capi. | |
---|---|---|
-92.50% | 64.89K | |
+50.30% | 56.69B | |
-3.67% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+14.30% | 25.59B | |
-21.83% | 18.59B | |
-0.06% | 12.39B | |
+26.49% | 11.99B | |
+23.18% | 11.88B |
- Stock Market
- Equities
- ALNEV Stock
- News NEOVACS
- Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023